Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P70 is a processed pseudogene derived from the ribosomal protein L21. The canonical RPL21 gene encodes a structural constituent of the large (60S) ribosomal subunit essential for cytoplasmic protein synthesis in human cells[1][3]. Pseudogenes like RPL21P70 are nonfunctional remnants, resulting from gene duplication or retrotransposition, and typically do not encode proteins or contribute directly to cell biology or disease. RPL21P70 does not participate in protein synthesis, does not serve as a receptor, enzyme, transporter, or other therapeutic target, and is not associated with clinical conditions or drug response. In summary: RPL21P70 should not be considered a conventional molecule or receptor target; it is a pseudogene and lacks therapeutic or biological function of interest for research or drug development[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 70 (RPL21P70).